Skip to main content
News

Rockland Immunochemicals and LIMR Development Form Antibody Commercialization Partnership – MarketWatch

By April 18, 2012No Comments
Rockland Immunochemicals

Rockland Immunochemicals

Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody-based tools for basic research, diagnostic assay development and preclinical studies is pleased to announce a new licensing venture with LIMR Development, Inc. (LDI), the business development subsidiary of the Lankenau Institute for Medical Research (LIMR).

Rockland Immunochemicals will market LDI’s entire portfolio of LIMR monoclonal and polyclonal antibodies, which bind biomarkers crucial for cell signaling, immune system regulation, inflammatory responses, cellular metabolism, and cancer progression. Detailed product information can be found at http://rockland-inc.com/limr-collaboration.aspx . George Prendergast, PhD, President and CEO of LIMR, stated, “We are proud of the achievement of LDI to generate an agreement with Rockland to commercialize the high-quality research antibodies developed at LIMR.”

To read the full, original article click on this link: Rockland Immunochemicals and LIMR Development Form Antibody Commercialization Partnership – MarketWatch

{iframe}http://www.marketwatch.com/story/rockland-immunochemicals-and-limr-development-form-antibody-commercialization-partnership-2012-04-17{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.